Ad
related to: hep c new treatment options for multiple myeloma diagnosis guidelines listexplorepanel.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
multiple myeloma, AL amyloidosis DA or DAC: daunorubicin x 3 days plus ara-C x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia: DAT: daunorubicin, cytarabine (ara-C), tioguanine: Acute myeloid leukemia: DCEP dexamethasone, cyclophosphamide, etoposide, platinum agent
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.
Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.
multiple myeloma patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody [28] Moxetumomab pasudotox: Lumoxiti AstraZeneca: relapsed or refractory hairy cell leukemia (HCL) Loncastuximab tesirine: Zynlonta ADC Therapeutics
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma cells or other types of antibody-producing cells secrete a myeloma protein, i.e. an abnormal antibody, into the blood; this abnormal protein is usually found during standard laboratory blood or urine tests.
Symptoms and laboratory findings suggestive of liver disease should prompt further tests and can thus help establish a diagnosis of hepatitis C infection early on. [16] Following the acute phase, the infection may resolve spontaneously in 10–50% of affected people; this occurs more frequently in young people and females. [15]
Treatment of patients with this POEMS syndrome variant who have evidence of bone lesions and/or myeloma proteins are the same as those for POEMS syndrome patients. In the absence of these features, treatment with rituximab , a monoclonal antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab , a monoclonal ...
Ad
related to: hep c new treatment options for multiple myeloma diagnosis guidelines listexplorepanel.com has been visited by 10K+ users in the past month